Dionne Takes Surface Logix Helm

Boston-based drug Surface Logix announced today that Keith Dionne taken the reins as president and CEO of the privately held developer of small-molecule drugs. Dionne was previously CEO of Alantos Pharmaceuticals, which was acquired by by Amgen for some $300 million; he also spent 7 years in various roles at Cambridge, MA-based Millennium Pharmaceuticals.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy